|Trade names||Oxervate, Sentinel|
|Other names||Recombinant human nerve growth factor; rhNGF; human beta-nerve growth factor (beta-NGF)-(1-118) peptide (non-covalent dimer) produced in Escherichia coli|
|Chemical and physical data|
|Molar mass||13266.94 g/mol g·mol−1|
Cenegermin (planned brand names Oxervate, Sentinel), also known as recombinant human nerve growth factor (rhNGF), is a recombinant form of human nerve growth factor (NGF). It was approved in the European Union as an eye drop formulation for the treatment of moderate or severe neurotrophic keratitis in adults on 6 July 2017. As a recombinant form of NGF, cenegermin is a peripherally selective agonist of the TrkA and LNGFR (p75NTR) which must be administered parenterally. In addition to neurotrophic keratitis, cenegermin is also under development for the treatment of dry eyes, retinitis pigmentosa, and glaucoma. It was developed by Anabasis Pharma, Dompé Farmaceutici, and Ospedale San Raffaele.
- "Authorisation details". European Medicines Agency. Retrieved 19 February 2018.
- Cenegermin - AdisInsight
- Dompé receives positive CHMP opinion in Europe for Oxervate® (cenegermin eye drops) for the treatment of adult patients with moderate or severe neurotrophic keratitis
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|